➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 8,003,792

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,003,792
Title:Bicyclic anilide spirolactam CGRP receptor antagonists
Abstract: The present invention is directed to compounds of Formula I: ##STR00001## (where variables A.sup.1, A.sup.2, B, J, K, m, n, R.sup.4, R.sup.5a, R.sup.5b and R.sup.5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Inventor(s): Bell; Ian M. (Harleysville, PA), Theberge; Cory R. (King of Prussia, PA), Stump; Craig A. (Pottstown, PA), Zhang; Xufang (Dresher, PA), Gallicchio; Steven N. (Wyndmoor, PA), Zartman; C. Blair (Hatfield, PA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:11/662,703
Patent Claims:see list of patent claims

Details for Patent 8,003,792

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2024-09-13 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2024-09-13 RX Orphan search
Jubilant Hollisterstier Llc POSITIVE SKIN TEST CONTROL - HISTAMINE histamine INJECTION 103891 1 1995-06-15   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2024-09-13 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.